contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


ortivus-ab-year-end-report-january-december-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Ortivus är verksamt inom hälsovårdssektorn. Bolaget är specialiserade inom utvecklingen av mobila lösningar för sjukvården. Tjänsterna innefattar exempelvis övervaknings- och kommunikationslösningar som vidare används inom beslut- och stödsystem. Idag vidaresäljs lösningarna under flertalet varumärken med vardera affärsinriktning. Störst verksamhet innehas inom Norden, samt Europa. Ortivus etablerades under 1985 och har sitt huvudkontor i Danderyd.

Ortivus

“We enter 2026 with a strengthened balance sheet, a more efficient organisation, and a portfolio of innovations already making a difference.”October-December 2025Net sales decreased by 12% and...

<div class="mfn-preamble"><p><em><strong>“We enter 2026 with a strengthened balance sheet, a more efficient organisation, and a portfolio of innovations already making a difference.”</strong></em></p></div><div class="mfn-body"><p><strong>October-December 2025</strong></p><ul><li>Net sales decreased by 12% and amounted to SEK 18.8 (21.3) million.</li><li>The gross margin increased to 41 (21)%.</li><li>EBITDA amounted to SEK -3.9 (-4.4) million.</li><li><em>Adjusted EBITDA* amounted to SEK -1.6 (2.3) million.</em></li><li>Net profit after tax amounted to SEK -7.0 (-9.6) million.</li><li>Earnings per share before and after dilution amounted to SEK -0.10 (-0.22).</li></ul><p>&nbsp;<br><strong>January-December 2025</strong></p><ul><li>Net sales decreased by 9% and amounted to SEK 73.4 (80.4) million.</li><li>The gross margin amounted to 40 (35)%.</li><li>EBITDA amounted to SEK -15.9 (-13.8) million.</li><li><em>Adjusted EBITDA* amounted to SEK -8.6 (-4.9) million.</em></li><li>Net profit after tax amounted to SEK -21.9 (-24.9) million.</li><li>Earnings per share before and after dilution amounted to SEK -0.43 (-0.56).</li></ul><p>&nbsp;<br><strong>Significant events during and after fourth quarter</strong></p><ul><li>The directed rights issue, which was registered on 3 November and fully subscribed, raised SEK 52 million for the Company after transaction costs.</li><li>Items of a non-recurring nature impacted the quarterly result by SEK 2.2 million. For the full year, non-recurring items amounted to SEK 7.4 million.</li><li>On 13 January, it was announced that Ponderus Invest AB holds 80 per cent of the Company following the mandatory cash offer made in accordance with the Takeover Code.</li><li>In February, Minni Raij joined the Company as Chief Financial Officer.</li><li>The Board of Directors proposes that no dividend be paid for the financial year 2025.</li></ul></div><div class="mfn-footer mfn-contacts mfn-060ef24c5677"><p><strong class="mfn-heading-1">Contacts</strong></p><hr><p>For further information, please contact</p><p>Gustaf Nordenhök, CEO</p><p>Phone +46 8 446 45 00</p></div><div class="mfn-footer mfn-about mfn-92fa32462855"><p><strong class="mfn-heading-1">About Ortivus</strong></p><hr><p>Ortivus has extensive experience in mobile communication solutions and a unique understanding of clinical healthcare. We develop interactive and user-friendly solutions that support diagnostics, increase efficiency, and deliver long-term cost savings for healthcare providers. By integrating our solutions with electronic health records, dispatch systems, and national registries, we ensure fast and secure information management, a crucial factor in creating a more integrated care process.&nbsp;<br>&nbsp;<br>Our solutions save valuable time for healthcare professionals, optimise resource use, and reduce the need for avoidable patient transports, resulting in more cost-effective and patient-centred care. With our combination of advanced technology and deep clinical expertise, we support our customers in meeting the healthcare challenges of today and tomorrow.</p><p>Ortivus Class A and Class B shares are listed on the NASDAQ First North Growth Market and the company’s Certified Adviser is FNCA Sweden AB.<br>&nbsp;<br>Read more about our solutions at <a rel="noopener" href="http://www.ortivus.com/">www.ortivus.com</a></p></div><div class="mfn-footer mfn-regulatory mfn-regulatory-mar"><p><em>This information is information that Ortivus is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-02-19 08:30 CET.</em></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/b787adef-3e45-417a-a7dc-0f0eefee737a/year-end-report-fourth-quarter-and-full-year-2025.pdf" class="mfn-primary">Year End Report Fourth Quarter And Full Year 2025</a></p></div>